BUZZ-AstraZeneca: falls as FDA staff flag diabetes drug risk
** AstraZeneca (NYSE: AZN - news) off 2 pct as U.S. FDA staff say its diabetes drug Onglyza appears to be associated with an increased rate of death
** A clinical study known as SAVOR found in 2013 that Onglyza might be linked to heart failure, where the heart fails to pump blood adequately
** Now (NYSE: DNOW - news) the issue is revived as a threat to the company's important diabetes business, since an FDA advisory panel will consider results of cardiovascular outcomes trials involving such DPP-IV inhibitor drugs on April 14 (RM (LSE: RM.L - news) : ben.hirschler.thomsonreuters.com@reuters.net)